Mary-Claire King

Last updated
Mary-Claire King
MCK WH.jpg
Mary-Claire King in 2016
Born (1946-02-27) February 27, 1946 (age 78)
Illinois, United States
NationalityAmerican
Alma mater Carleton College
University of California, Berkeley
University of California, San Francisco
Known for Breast cancer gene discovery
Forensic genetics for human rights
Awards Gruber Prize in Genetics (2004)
Heineken Prize (2006)
Weizmann Award (2006)
Pearl Meister Greengard Prize (2010)
Lasker Award (2014)
National Medal of Science (2014, awarded 2016)
Shaw Prize in Medicine (2018)
Scientific career
Fields Human genetics
Institutions University of Washington, University of California, Berkeley
Thesis Protein polymorphisms in chimpanzee and human evolution  (1973)
Doctoral advisor Allan Wilson
Website UW Genome Sciences page
External videos
Nuvola apps kaboodle.svg "Meet Dr. Mary-Claire King, Ground-Breaking Geneticist and Tireless Human Rights Activist", World Science Festival, March 5, 2014

Mary-Claire King (born February 27, 1946) [1] is an American geneticist. She was the first to show that breast cancer can be inherited due to mutations in the gene she called BRCA1 . She studies human genetics and is particularly interested in genetic heterogeneity and complex traits. [2] She studies the interaction of genetics and environmental influences and their effects on human conditions such as breast and ovarian cancer, inherited deafness, schizophrenia, [3] HIV, systemic lupus erythematosus and rheumatoid arthritis. [4] She has been the American Cancer Society Professor of the Department of Genome Sciences and of Medical Genetics in the Department of Medicine at the University of Washington since 1995. [5]

Contents

Besides known for her accomplishment in identifying breast cancer genes, King is also known for demonstrating that humans and chimpanzees are 99% genetically identical and for applying genomic sequencing to identify victims of human rights abuses. In 1984, in Argentina, she began working in identifying children who had been stolen from their families and adopted illegally under the military dictatorship during the Dirty War (1976–1983). She has received many awards, including the Lasker Award and the National Medal of Science. In 2002, Discover magazine recognized King as one of the 50 most important women in science. [6]

Early life

Mary-Claire King was born on February 27, 1946, to Harvey and Clarice King of Wilmette, Illinois, near Chicago. Her father worked for Standard Oil of Indiana. [1] When King was 15 years old, her childhood best friend died of cancer. King became interested in science in the hope of learning enough to prevent and treat such illnesses. [7]

Education

King received her undergraduate degree in mathematics (cum laude) from Carleton College, Phi Beta Kappa, in 1967. [8] [9]

King was accepted into the graduate program at the University of California, Berkeley, and soon became politically active. She helped to organize protests against U.S. involvement in the Vietnam War in 1970. She says: "The single most effective thing we did was on the day after the US invaded Cambodia, we got out our suit jackets and shirtwaist dresses – not clothes that any of us had worn since coming to Berkeley – and went to the synagogues and churches and by the end of Sunday we had 30,000 letters opposing the action." [10] She dropped out of university briefly after the National Guard was sent in against student protestors. [11] [12]

She spent a year doing consumer advocacy work for Ralph Nader, investigating pesticide use and its effects on farm workers. [11] [12]

After her return to Berkeley, advisor Allan Wilson persuaded her to switch from mathematics to genetics. [13] King had been introduced to genetics by professor Curt Stern, in the last class he taught before his retirement. [14] In her doctoral work at Berkeley, King demonstrated through comparative protein analysis that chimpanzees and humans were 99% genetically identical. King's work supported Allan Wilson's view that chimpanzees and humans diverged only five million years ago, and King and Wilson suggested that gene regulation was likely responsible for the significant differences between the species. [15] [16] [17] King completed her thesis in 1972, and received her doctorate in genetics from the University of California, Berkeley in 1973. [9] [17]

Next King went to Santiago, Chile to teach at the Universidad de Chile as part of a University of California-University of Chile exchange program. Her time there was cut short when the Chilean government of Salvador Allende was overthrown in a CIA-backed military coup on September 11, 1973. King and her husband Robert Colwell returned to Berkeley in late December. [13] [18] She later learned that a number of her colleagues and students had either disappeared or been killed. [19]

King accepted a postdoctoral position at the University of California, San Francisco (UCSF), to work with Nicholas L. Petrakis. As of January 1, 1974, King began to work on the problem of why breast cancer tends to appear in families. [18] [13]

Family

King's younger brother Paul King, a mathematician and business consultant, was the CEO of Vanalco in Vancouver, Washington. [20]

King married ecologist Robert K. Colwell in 1973. [21] They have one child, Emily King Colwell, born in 1975. [22] Emily studied the evolution of languages at Brown University with a B.A. in linguistics. King and Colwell divorced in 1983.

Career

King accepted a faculty appointment at the University of California, Berkeley, as professor of genetics and epidemiology in 1976. She remained at UC Berkeley until 1995, when she accepted an appointment as the American Cancer Society Professor at the University of Washington. [5] She also served on the Life Sciences jury for the Infosys Prize in 2015.

Research

Breast cancer

From 1974 to 1990, King carried out years of painstaking research, seeking a genetic marker, an identifiable piece of genetic material, that tended to accompany the presence of breast cancer in families. [23] For much of that time, the predominant theory was that cancer was viral. [7] Most scientists disregarded or attacked her ideas. The idea that genetic patterns could be linked to the incidence of complex diseases was considered an unlikely long shot. [22] Genetics had been recognized as significant in diseases with a simple genetic tie, such as Huntington's disease, cystic fibrosis, and sickle-cell anemia, but researchers were skeptical about the usefulness of genetics in studying more common and complex diseases involving both multiple genetic factors and environmental influences. King sometimes worried that she was going down a blind alley in trying to study the interplay of genetics with a complex human disease. [22]

Nonetheless, the search for the breast cancer susceptibility gene was moving forward with firm steps in King's lab and accelerating in the mid-1980s. On the basis of a series of unselected breast cancer cases and their family history, in 1988, King's team published a genetic epidemiological model for breast cancer, demonstrating the theoretical existence of a major dominant gene that conferred a high degree of susceptibility to breast cancer in a subset of the population. Applying this genetic penetrance model and using the genotyping technology available at the time, King's team evaluated more than 170 genetic markers, utilizing the gene mapping technique known as linkage analysis. When they in 1990 finally found a genetic marker that showed strong evidence in a subset of families, King's group demonstrated that a single gene on chromosome 17 could be linked to many breast and ovarian cancers, and that genetic heterogeneity was present in breast cancer etiology. A team member suggested that they reorganize their data by age of onset, as in the study cohort, the families in which members had developed cancer at a relatively young age tended to show stronger evidence of linkage to this locus. The idea was that early cases might be more likely to reflect a genetic component, in contrast to sporadic mutations that might occur at any age or even accrue over time. As many as 5–10% of all cases of breast cancer may be hereditary. [24] [23] [25] In 1991 King officially named the gene BRCA1. [26] Her discovery paved the way for identification of the gene sequence. In September 1994, Myriad Genetics published a paper on the positional cloning of the sequence after a highly publicized "race" by groups of scientists. [27] [28] [26] In December 1994, King and her collaborators published results based on a second cohort of families. [28] [29] A second gene, BRCA2, was also found. [27] These two genes, BRCA1 and BRCA2, work to clean up cells in the body that have been harmed by things such as tobacco or just help clean the cells because they have aged. When these genes do not perform these functions, cells will grow and divide quickly, leading to some types of cancers. [30] [31] Both genes worked to suppress the development of cancer tumors, but certain types of genetic mutations could prevent them from doing so. [24]

In 1996, with support from the Breast Cancer Research Foundation (BCRF) Mary-Claire King and social worker Joan Marks began the New York Breast Cancer Study, which definitively determined that incidence of breast and ovarian cancer was linked to inherited mutations of the genes BRCA1 and BRCA2. The researchers studied women of Ashkenazi Jewish ancestry in New York, a group that was known to have a very high incidence of breast cancer (up to an 80% risk by age 70, compared with 12% in the general population). [32] [33] She has also studied the incidence of breast cancer in Palestinian women. [34]

The discovery of the "breast cancer gene" revolutionized the study of numerous other diseases and phenotypes. The model and technique King developed to identify BRCA1 has since proven valuable in the study of many other illnesses and conditions. [18] King's contributions have made it possible for people to be informed of genetic information that then can aid them in making choices best for themselves and for their future. [35] [22]

King also worked on a project studying the mutations of genes linked to breast cancer inheritance in Nigerian women between March 1998 and 2014. King's team decided to do this research on the grounds that more people die in Nigeria from triple negative breast cancer that is diagnosed at a later stage than other, more educated regions of the world, such as Europe or America. At the finish of this study, King's team was still unsure of the reason for such high levels of Triple-negative breast cancer, since many of the people diagnosed were not showing mutations in the BRCA1 gene. Her study supported the idea that genomic sequencing could be useful as a tool to help detect gene mutations early and be proactive in letting those who have high risks for breast cancer know ahead of time. [36]

Hearing loss and deafness

Since 1990, King has been working in collaboration with scientists around the world to identify genetic causes of hearing loss and deafness. They localized the first nonsyndromic deafness-related gene, DFNA1, in a Costa Rica kindred, [37] and successfully cloned the gene in 1999. [38] [39] [40]

King continues to work with scientists Karen Avraham at Tel Aviv University in Israel and Moien Kanaan at Bethlehem University in Palestine, modeling international scientific cooperation in conjunction with conducting scientific research. Hereditary deafness is common among some Palestinian and Israeli communities, providing good study populations to understand the genetics of this condition. [41] [42]

We understand that working together transcends politics. It's possible to do beautiful useful science together, even between countries that are in conflict.

— Mary-Claire King, 2018 [41]

The genetic etiology of hearing loss is extremely heterogeneous, with a very high degree of complexity among Middle Eastern populations, presenting a different level of challenge for genetic analysis. King's collaboration with scientists in Israel and Palestine has resolved the complex web of different genes and varying modes of transmission for this common phenotype among many kindreds in the communities in that region.

Schizophrenia

King in recent years has developed a deep interest in studying the genetic factors influencing schizophrenia. In collaboration with other scientists including Judith L. Rapoport, Jonathan Sebat, and Deborah L. Levy, she has discovered evidence that suggests that schizophrenia may be linked to the presence of genetic mutations called copy number variations (CNVs) in pathways involved in neural development. A percentage of such variations may occur spontaneously as a result of copying errors in cells. [43] [44] [45] [46]

Human Genome Diversity Project

King has also worked on the Human Genome Diversity Project, led by Luca Cavalli-Sforza. The project seeks to delineate the distinctions among individuals in order to further understanding of human evolution and historical migrations. [3] [47] [48] [49]

Romanov exhumation

King is well known for her work on the forensic determination of individual identity, in particular the use of mitochondrial DNA from teeth. [50] King was invited to participate in DNA investigations of the first analysis of Romanov remains exhumed in 1991 in Ekaterinburg, Russia. [51]

Human rights work

King first applied her genetics skills to human rights work in 1984, when she and her lab began working with Abuelas de Plaza de Mayo (Grandmothers of Plaza de Mayo) in Argentina. She used dental genetics to identify missing persons, ultimately identifying 59 children and helping return them to their biological families. Most had been born to women in prison who had been persecuted as political dissidents and were later "disappeared" by the Argentine military dictatorship during the eight-year "Dirty War" from 1976 to 1983. These children were often illegally "adopted" by military families without their mother's or other family consent. [7] [3]

Beginning in 1977 Las Abuelas ("the grandmothers") had gathered to protest the disappearance of their grandchildren and seek their return. Every Thursday, they marched to the central plaza in Buenos Aires ("Plaza de Mayo") to demand the return of their grandchildren, and they began gathering data trying to identify the many missing children (estimated to be 400–500). [3]

By the time King joined the project, the dictatorship had been replaced by a democratic government, but it required proof of kinship to remove children from families and return them to biological families. King's technique, using mitochondrial DNA and human leukocyte antigen serotyping genetic markers from dental samples, proved invaluable. The Supreme Court of Argentina in 1984 determined that King's test had positively identified the relationship of Paula Logares to her family, establishing the precedent for the ultimate reunification of dozens of families with their stolen children. [52] [3]

Since 1984, this technique has become a major method for genetic identification of the deceased as well as the living. In 1993 King used the technique to identify the remains of individuals massacred in the village of El Mozote, El Salvador. More than 750 adults and children were massacred and buried in mass graves by US-trained Salvadoran soldiers [3] of the Atlácatl Battalion. [53]

King has worked with numerous human rights organizations, such as Physicians for Human Rights and Amnesty International, to identify missing people in countries including Argentina, [54] Chile, El Salvador, Guatemala, Haiti, Honduras, Mexico, Rwanda, the Balkans (Croatia and Serbia), and the Philippines. [55] [56] King's lab has also provided DNA identification for the U.S. Army, [57] the United Nations, [58] and the U.N.'s war crimes tribunals. [59]

King has been highly critical of genetic patenting, a practice which was ruled against by the U.S. Supreme Court in 2013, on the grounds that "genes are natural products and cannot be patented". [7] [60]

Awards, prizes, and honors

Dr. King has won numerous awards, prizes, and honors for her scientific and humanitarian work, including:. [61]

Honorary degrees

Notable professional service

King has five patents and over 250 peer-reviewed journal articles.

Related Research Articles

<span class="mw-page-title-main">Penetrance</span> Proportion of individuals that express the trait associated with a gene variant

Penetrance in genetics is the proportion of individuals carrying a particular variant of a gene (genotype) that also expresses an associated trait (phenotype). In medical genetics, the penetrance of a disease-causing mutation is the proportion of individuals with the mutation that exhibit clinical symptoms among all individuals with such mutation. For example: If a mutation in the gene responsible for a particular autosomal dominant disorder has 75% penetrance, then 75% of those with the mutation will go on to develop the disease, showing its phenotype, whereas 25% will not. 

<span class="mw-page-title-main">BRCA1</span> Gene known for its role in breast cancer

Breast cancer type 1 susceptibility protein is a protein that in humans is encoded by the BRCA1 gene. Orthologs are common in other vertebrate species, whereas invertebrate genomes may encode a more distantly related gene. BRCA1 is a human tumor suppressor gene and is responsible for repairing DNA.

<span class="mw-page-title-main">Mary F. Lyon</span> English geneticist (1925–2014)

Mary Frances Lyon was an English geneticist best known for her discovery of X-chromosome inactivation, an important biological phenomenon.

<span class="mw-page-title-main">Myriad Genetics</span> American biotechnology company

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.

<span class="mw-page-title-main">Hereditary breast–ovarian cancer syndrome</span> Medical condition

Hereditary breast–ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal levels of breast cancer, ovarian cancer and additional cancers in genetically related families. It accounts for 90% of the hereditary cancers. The hereditary factors may be proven or suspected to cause the pattern of breast and ovarian cancer occurrences in the family. The name HBOC may be misleading because it implies that this genetic susceptibility to cancer is mainly in women. In reality, both sexes have the same rates of gene mutations and HBOC can predispose to other cancers including prostate cancer and pancreatic cancer. For this reason, the term "King syndrome" has recently come into use. The new name references Mary-Claire King who identified the genes BRCA1 and BRCA2.

<span class="mw-page-title-main">BRIP1</span> Mammalian protein found in Homo sapiens

Fanconi anemia group J protein is a protein that in humans is encoded by the BRCA1-interacting protein 1 (BRIP1) gene.

Genetic heterogeneity occurs through the production of single or similar phenotypes through different genetic mechanisms. There are two types of genetic heterogeneity: allelic heterogeneity, which occurs when a similar phenotype is produced by different alleles within the same gene; and locus heterogeneity, which occurs when a similar phenotype is produced by mutations at different loci.

<i>BRCA</i> mutation Medical condition

A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumour suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast–ovarian cancer syndrome in affected persons. Only 5–10% of breast cancer cases in women are attributed to BRCA1 and BRCA2 mutations, but the impact on women with the gene mutation is more profound. Women with harmful mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal. The risk of breast and ovarian cancer is higher for women with a high-risk BRCA1 mutation than with a BRCA2 mutation. Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor.

Sir Michael Rudolf Stratton, is a British clinical scientist and the third director of the Wellcome Trust Sanger Institute. He currently heads the Cancer Genome Project and is a leader of the International Cancer Genome Consortium.

Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.

<i>Decoding Annie Parker</i> 2013 American film

Decoding Annie Parker is a 2013 American drama film written and directed by Steven Bernstein. The film stars Samantha Morton, Helen Hunt and Aaron Paul. The film tells the story of Annie Parker and the discovery of the BRCA1 breast cancer gene.

Ashok Venkitaraman is a British cancer researcher of Indian origin. He is the Director of the Cancer Science Institute of Singapore, a Distinguished Professor of Medicine at the National University of Singapore, and Program Director at A*STAR, Singapore. From 1998 to 2020, he was the inaugural holder of the Ursula Zoellner Professorship of Cancer Research at the University of Cambridge, a Professorial Fellow at Pembroke College, Cambridge, and from 2006 to 2019, was the Director of the Medical Research Council Cancer Unit.

A variant of uncertainsignificance (VUS) is a genetic variant that has been identified through genetic testing but whose significance to the function or health of an organism is not known. Two related terms are "gene of uncertain significance" (GUS), which refers to a gene that has been identified through genome sequencing but whose connection to a human disease has not been established, and "insignificant mutation", referring to a gene variant that has no impact on the health or function of an organism. The term "variant' is favored in clinical practice over "mutation" because it can be used to describe an allele more precisely. When the variant has no impact on health, it is called a "benign variant". When it is associated with a disease, it is called a "pathogenic variant". A "pharmacogenomic variant" has an effect only when an individual takes a particular drug and therefore is neither benign nor pathogenic.

Wendy K. Chung is an American clinical and molecular geneticist and physician. She is the Chair of the Department of Pediatrics at Boston Children's Hospital and is on the faculty at Harvard Medical School. She is the author of 700 peer-reviewed articles and 75 chapters and has won several awards as a physician, researcher, and professor. Chung helped to initiate a new form of newborn screening for spinal muscular atrophy which is used nationally and was among the plaintiffs in the Supreme Court case which banned gene patenting.

Charis Eng is a Singapore-born physician-scientist and geneticist at the Cleveland Clinic, notable for identifying the PTEN gene. She is the Chairwoman and founding Director of the Genomic Medicine Institute of the Cleveland Clinic, founding Director and attending clinical cancer geneticist of the institute’s clinical component, the Center for Personalized Genetic Healthcare, and Professor and Vice Chairwoman of the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine.

Douglas F. Easton FMedSci is a British epidemiologist who conducts research on the genetics of human cancers. He is Professor of Genetic Epidemiology and Centre for Cancer Genetic Epidemiology at the University of Cambridge. He founded Cambridge's Cancer Research UK Genetic Epidemiology Unit in 1995, and was a Principal Research Fellow there from 2001 to 2011. He is a Professorial Fellow of Homerton College, Cambridge.

Maria Jasin is a developmental biologist at the Memorial Sloan Kettering Cancer Center. She is known for studying homologous recombination, a method in which double-strand breaks in DNA strands are repaired, and for discovering the role of BRCA1 and BRCA2 in cancers.

<span class="mw-page-title-main">Jórunn Erla Eyfjörð</span> Icelandic academic

Jórunn Erla Eyfjörð is an Icelandic molecular biologist and professor emerita at the Faculty of Medicine of the University of Iceland. She is known for her research on breast cancer genetics.

<span class="mw-page-title-main">Wylie Burke</span> American geneticist

Wylie Burke is a Professor Emerita and former Chair of the Department of Bioethics and Humanities at the University of Washington and a founding co-director of the Northwest-Alaska Pharmacogenomics Research Network, which partners with underserved populations in the Pacific Northwest and Alaska.

Peter H. Byers is an American geneticist, physician, and researcher of connective tissue disorders. He is a professor of medicine, a professor of pathology, and an adjunct professor of genome sciences at the University of Washington.

References

  1. 1 2 Yount, Lisa (2008). "Mary-Claire King" (PDF). A to Z of women in science and math. New York: Facts On File. pp. 153–156. ISBN   978-0816066957.
  2. ↑ "Mary-Claire King Professor of Genome Sciences and of Medicine (Medical Genetics)". UW Genome Sciences. Retrieved 12 February 2019.
  3. 1 2 3 4 5 6 Angier, Natalie (April 27, 1993). "SCIENTIST AT WORK: Mary-Claire King; Quest for Genes and Lost Children". The New York Times. Retrieved 19 February 2019.
  4. ↑ Bock, Paula (May 19, 2016). "The plan of all plans: Mary-Claire King and her team explore secrets of DNA". Pacific NW Magazine. Retrieved 19 February 2019.
  5. 1 2 "Mary-Claire King, PhD". Division of Medical Genetics, University of Washington. Archived from the original on 19 February 2021. Retrieved 14 February 2019.
  6. ↑ Svitil, Kathy (13 November 2002). "The 50 Most Important Women in Science". Discover. Retrieved 21 December 2014.
  7. 1 2 3 4 Dreifus, Claudia (February 9, 2015). "A Never-Ending Genetic Quest". The New York Times. Retrieved 19 February 2019.
  8. ↑ "Life and Science". Carleton College Voice. 2015. Retrieved 18 February 2019.
  9. 1 2 "Distinguished Achievement Award Mary-Claire King" (PDF). Carleton College. Retrieved 12 February 2019.
  10. ↑ Jaffe, Sam (March 15, 2004). "Mary-Claire King". The Scientist. Retrieved 29 November 2016.
  11. 1 2 Zhu, Meilin (2017-08-23). "Mary-Claire King (1946– )". The Embryo Project Encyclopedia. Retrieved 12 February 2019.
  12. 1 2 3 "Mary-Claire King (1946), USA". Royal Netherlands Academy of Arts and Sciences (KNAW). Archived from the original on 13 February 2019. Retrieved 29 November 2016.
  13. 1 2 3 Elliott, Ellen. "Women in Science: Mary-Claire King". The Jackson Laboratory. Retrieved 12 February 2019.
  14. ↑ "Autobiography of Mary-Claire King". The Shaw Prize. Archived from the original on 13 February 2019. Retrieved 12 February 2019.
  15. ↑ King, M.; Wilson, A. (1975). "Evolution at two levels in humans and chimpanzees". Science. 188 (4184): 107–116. Bibcode:1975Sci...188..107K. doi:10.1126/science.1090005. PMID   1090005.
  16. ↑ Gilad, Y.; Oshlack, A.; Smyth, G. K.; Speed, T. P.; White, K. P. (2006). "Expression profiling in primates reveals a rapid evolution of human transcription factors". Nature. 440 (7081): 242–245. Bibcode:2006Natur.440..242G. doi: 10.1038/nature04559 . PMID   16525476.
  17. 1 2 Mary-Claire King, Protein polymorphisms in chimpanzee and human evolution, Doctoral dissertation, University of California, Berkeley (1973).
  18. 1 2 3 "Q&A With Dr. Mary-Claire King". Breast Cancer Research Foundation (BCRF). July 7, 2014. Retrieved 12 February 2019.
  19. 1 2 "KATHOLIEKE UNIVERSITEIT LEUVEN Laudatio for Professor Mary-Claire King Pronounced in Leuven on 2 February 2006 by Professor Dr. Gert Matthijs, promoter" (PDF). Katholieke Universiteit. Retrieved 29 November 2016.
  20. ↑ McHale, Laurie (1996). "Putting the Puzzle Together". Columns: The University of Washington Alumni Magazine. Retrieved 29 November 2016.
  21. ↑ "Robert K. Colwell Homepage".
  22. 1 2 3 4 Entine, Jon (2007). Abraham's children : race, identity, and the DNA of the chosen people (1st ed.). New York: Grand Central Pub. pp. 270–289. ISBN   978-0446580632 . Retrieved 13 February 2019.
  23. 1 2 "Mary-Claire King Genetic Breast Cancer Detection". Lemelson-MIT Program. Retrieved 14 February 2019.
  24. 1 2 Batt, Sharon (2003). Patient no more : the politics of breast cancer. Gynergy. pp. 170–176. ISBN   978-0921881308 . Retrieved 14 February 2019.
  25. ↑ Hall, J.; Lee, M.; Newman, B.; Morrow, J.; Anderson, L.; Huey, B.; King, M. (1990). "Linkage of early-onset familial breast cancer to chromosome 17q21". Science. 250 (4988): 1684–1689. Bibcode:1990Sci...250.1684H. doi:10.1126/science.2270482. PMID   2270482.
  26. 1 2 Miki, Y; Swensen, J; Shattuck-Eidens, D; Futreal, P.; Harshman, K; Tavtigian, S; Liu, Q; Cochran, C; Bennett, L.; Ding, W; et, al. (7 October 1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi: 10.1126/science.7545954 . PMID   7545954.
  27. 1 2 Gold, E Richard; Carbone, Julia (April 2010). "Myriad Genetics: In the eye of the policy storm". Genetics in Medicine. 12 (4 Suppl): S39–S70. doi:10.1097/GIM.0b013e3181d72661. PMC   3037261 . PMID   20393310.
  28. 1 2 King, M.-C. (27 March 2014). ""The Race" to Clone BRCA1". Science. 343 (6178): 1462–1465. Bibcode:2014Sci...343.1462K. doi:10.1126/science.1251900. PMID   24675952. S2CID   206555895.
  29. ↑ Friedman, Lori S.; Ostermeyer, Elizabeth A.; Szabo, Csilla I.; Dowd, Patrick; Lynch, Eric D.; Rowell, Sarah E.; King, Mary-Claire (December 1994). "Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families". Nature Genetics. 8 (4): 399–404. doi:10.1038/ng1294-399. PMID   7894493. S2CID   2863113.
  30. ↑ "BRCA1 gene BRCA1, DNA repair associated". Genetics Home Reference. National Library of Medicine. Retrieved 1 May 2019.
  31. ↑ "BRCA: The Breast Cancer Gene". National Breast Cancer Foundation. Retrieved 1 May 2019.
  32. ↑ "Landmark study offers new information about breast cancer genes Helps participants understand options". EurekaAlert. Sarah Lawrence College. 23 October 2003. Retrieved 14 February 2019.
  33. ↑ King, M.-C. (24 October 2003). "Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2". Science. 302 (5645): 643–646. Bibcode:2003Sci...302..643K. doi:10.1126/science.1088759. PMID   14576434. S2CID   33441900.
  34. ↑ Lolas Hamameh, Suhair; Renbaum, Paul; Kamal, Lara; Dweik, Dima; Salahat, Mohammad; Jaraysa, Tamara; Abu Rayyan, Amal; Casadei, Silvia; Mandell, Jessica B.; Gulsuner, Suleyman; Lee, Ming K.; Walsh, Tom; King, Mary-Claire; Levy-Lahad, Ephrat; Kanaan, Moein (15 August 2017). "Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53". International Journal of Cancer. 141 (4): 750–756. doi:10.1002/ijc.30771. PMC   5526459 . PMID   28486781.
  35. ↑ Shute, Nancy (March 27, 2014). "How Being Ignored Helped A Woman Discover the Breast Cancer Gene". All Things Considered. Retrieved 29 November 2016.
  36. ↑ Zheng, Yonglan; Walsh, Tom; Gulsuner, Suleyman; Casadei, Silvia; Lee, Ming K.; Ogundiran, Temidayo O.; Ademola, Adeyinka; Falusi, Adeyinka G.; Adebamowo, Clement A. (October 2018). "Inherited Breast Cancer in Nigerian Women". Journal of Clinical Oncology. 36 (28): 2820–2825. doi:10.1200/jco.2018.78.3977. ISSN   0732-183X. PMC   6161833 . PMID   30130155.
  37. ↑ Lynch, E. D. (14 November 1997). "Nonsyndromic Deafness DFNA1 Associated with Mutation of a Human Homolog of the Drosophila Gene diaphanous". Science. 278 (5341): 1315–1318. Bibcode:1997Sci...278.1315L. doi:10.1126/science.278.5341.1315. PMID   9360932.
  38. ↑ "Pioneers of Science: Dr Mary-Claire King" (PDF). Research Media. p. 21. Archived from the original (PDF) on 24 October 2022. Retrieved 19 February 2019.
  39. ↑ King, Mary-Claire. "G DFNA1 in Inherited Hearing Loss". Grantome. Retrieved 19 February 2019.
  40. ↑ "Nonsyndromic hearing loss". Genetics Home Reference. U.S. National Library of Medicine. Retrieved 19 February 2019.
  41. 1 2 "Science transcends Mideast turmoil with geneticist's help". UW Medicine Newsroom. University of Washington. April 30, 2018. Retrieved 19 February 2019.
  42. ↑ King, Mary-Claire. "Genetics of Hearing Loss in Palestinian Kindreds". Grantome. Retrieved 19 February 2019.
  43. ↑ Hamilton, Jonathan (March 27, 2008). "Genetic Link to Schizophrenia Discovered". All Things Considered. NPR. Retrieved 19 February 2019.
  44. ↑ "Mary-Claire King and Judith Rapoport: New Hope From Discovery of Rare Genetic Mutations in Schizophrenia". Brain and Behavior Research Foundation. April 1, 2010. Retrieved 19 February 2019.
  45. ↑ "CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia". EurekaAlert. 28 March 2008. Retrieved 19 February 2019.
  46. ↑ Walsh, T.; McClellan, J. M.; McCarthy, S. E.; Addington, A. M.; et al. (25 April 2008). "Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia". Science. 320 (5875): 539–543. Bibcode:2008Sci...320..539W. doi: 10.1126/science.1155174 . PMID   18369103. S2CID   14385126.
  47. ↑ Kreeger, Karen Young (Oct 14, 1996). "Proposed Human Genome Diversity Project Still Plagued By Controversy And Questions". The Scientist. Retrieved 19 February 2019.
  48. ↑ United States. Congress. Senate. Committee on Governmental Affairs (April 26, 1993). Human Genome Diversity Project : hearing before the Committee on Governmental Affairs, United States Senate, One Hundred Third Congress, first session, April 26, 1993. Washington: U.S. G.P.O. ISBN   9780160433344 . Retrieved 19 February 2019.
  49. ↑ Reardon, Jenny (June 2001). "The Human Genome Diversity Project: A Case Study in Coproduction" (PDF). Social Studies of Science. 31 (3): 357–388. doi: 10.1177/030631201031003002 . S2CID   145626708 . Retrieved 19 February 2019.
  50. ↑ Ginther, Charles; Issel-Tarver, Laurie; King, Mary-Claire (October 1992). "Identifying individuals by sequencing mitochondrial DNA from teeth". Nature Genetics. 2 (2): 135–138. doi: 10.1038/ng1092-135 . PMID   1303263. S2CID   28779140.
  51. 1 2 "Geneticist Mary-Claire King receives the 2013 Paul Ehrlich Prize". EurekaAlert. 14 March 2013. Retrieved 29 November 2016.
  52. ↑ Nelson, Bryn (May 12, 1997). "Using genetics for human rights". The Online Daily of the University of Washington. Retrieved 29 November 2016.
  53. ↑ Harvey-Blankenship, Michele; Pham, Phuong N.; Shigekane, Rachel (June 2010). "GENETIC TRACING, DISAPPEARED CHILDREN AND JUSTICE" (PDF). UNICEF. Innocenti Research Centre. Retrieved 12 February 2019.
  54. ↑ "Partnerships: Scientists Working With Human Rights Organizations". AAAS. Retrieved 19 February 2019.
  55. ↑ Owens, Kelly N; Harvey-Blankenship, Michelle; King, Mary-Claire (February 2002). "Genomic sequencing in the service of human rights". International Journal of Epidemiology. 31 (1): 53–58. doi: 10.1093/ije/31.1.53 . PMID   11914294.
  56. ↑ King, MC (1991). "An application of DNA sequencing to a human rights problem". Molecular Genetic Medicine. 1: 117–31. doi:10.1016/b978-0-12-462001-8.50009-0. ISBN   9780124620018. PMID   1842570.
  57. ↑ "Mary-Claire King Professor of Genome Sciences and of Medicine (Medical Genetics)". UW Genome Sciences. Retrieved 19 February 2019.
  58. 1 2 Ball, Howard (2015). Working in the killing fields : forensic science in Bosnia. Potomac Books. ISBN   9781612347189 . Retrieved 18 February 2019.
  59. 1 2 3 "Cancer Genetics Pioneers Mary-Claire King and Janet Rowley Receive 2010 Pearl Meister Greengard Prize" (PDF). ASHG. Retrieved 18 February 2019.[ permanent dead link ]
  60. ↑ Schubert, Charlotte (2003). "Profile: Mary-Claire King". Nature Medicine. 9 (6): 633. doi: 10.1038/nm0603-633 . PMID   12778148. S2CID   29601178.
  61. ↑ "Mary-Claire King, PhD". Breast Cancer Research Foundation. 2014-06-19. Archived from the original on 2016-11-30. Retrieved 2016-11-29.
  62. ↑ Canada Gairdner International Award 2021
  63. ↑ "ASHG Honors Mary-Claire King, PhD with the 2020 William Allan Award". ashg.org. July 13, 2020. Retrieved November 22, 2020.
  64. ↑ "ASHG honors Mary-Claire King with ASHG Advocacy Award". Eureka Alert. 16 July 2018. Retrieved 18 February 2019.
  65. ↑ "The Shaw Prize Lecture in Life Science and Medicine 2018". The Shaw Prize. Archived from the original on 13 February 2019. Retrieved 12 February 2019.
  66. ↑ "Press Release". The Shaw Prize. 13 July 2018. Retrieved 12 February 2019.
  67. ↑ "Laureates 2018". Dan David Prize. Retrieved 12 February 2019.
  68. ↑ "Trustees Sandra Faber And Mary-Claire King Receive Distinguished Awards". carnegiescience.edu. May 3, 2019. Retrieved November 18, 2020.
  69. ↑ "Mary-Claire". TNQ India. Archived from the original on 2018-07-18. Retrieved 2017-01-24.
  70. ↑ Urton, James (May 19, 2016). "Appeal of 'genetic puzzles' leads to National Medal of Science for UW's Mary-Claire King". UW News. University of Washington. Retrieved 12 February 2019.
  71. ↑ Donohue, Brian (December 22, 2015). "Mary-Claire King to receive National Medal of Science UW professor is world leader in cancer genetics, discovered BRCA1 gene for inherited breast cancer". UW Medicine News. Retrieved 12 February 2019.
  72. ↑ Siegel-Itzkovich, Judy (February 8, 2018). "US researchers receive Dan David Prize for outstanding cancer research". The Jerusalem Post. Retrieved 12 February 2019.
  73. ↑ "2016 Academy Prize Laureates". Turkish Academy of Sciences. Retrieved 12 February 2019.
  74. ↑ Thomas, Margetta. "World-renowned geneticist Mary-Claire King delivers address at HudsonAlpha". HudsonAlpha.org. HudsonAlpha Institute for Biotechnology. Retrieved 19 November 2014.
  75. ↑ Hurst, Jillian H. (8 September 2014). "Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science". Journal of Clinical Investigation. 124 (10): 4148–4151. doi:10.1172/JCI78507. PMC   4191015 . PMID   25196046.
  76. ↑ Strauss, Evelyn (2014). "2014 Lasker~Koshland Special Achievement Award in Medical Science Breast cancer genetics and human rights". Andrew and Mary Lasker Foundation. Retrieved 12 February 2019.
  77. ↑ "APS Member History". search.amphilsoc.org. Retrieved 2021-03-19.
  78. ↑ "2010 Honoree – Mary-Claire King". Cold Spring Harbor Laboratory. Archived from the original on 12 March 2017. Retrieved 29 November 2016.
  79. ↑ "Weizmann Women & Science Award presented to Dr. Mary-Claire King". EurekaAlert. 9 August 2006. Retrieved 29 November 2016.
  80. ↑ "Mary-Claire King elected to National Academy of Sciences". Hutch News. May 19, 2005. Retrieved 12 February 2019.
  81. ↑ "Past Recipients". Association for Molecular Pathology. Retrieved 2023-03-03.
  82. 1 2 "2004 Genetics Prize Mary-Claire King". Gruber Foundation. Retrieved 29 November 2016.
  83. ↑ "1999 Brinker International Awards forBreast Cancer Research Announced" (PDF). Frontline. Winter 2000. p. 1. Retrieved 18 February 2019.
  84. ↑ Woodward, Kristen (November 2, 2017). "Good News at Fred Hutch Celebrating faculty and staff achievements". Hutch News. Fred Hutch. Retrieved 14 February 2019. Past recipients of the Jill Rose Award include University of Washington breast cancer geneticist Dr. Mary Claire King
  85. ↑ "Mary-Claire King, PhD" (PDF). Pink Press. Breast Cancer ResearchFoundation. Summer 2006. p. 6. Retrieved 14 February 2019.
  86. ↑ "National Academy of Medicine (formerly Institute of Medicine)". UW Research. Retrieved 18 February 2019.
  87. 1 2 3 4 5 "Cover Legend" (PDF). Cancer Research. 54 (6). American Association for Cancer Research. March 15, 1994. Retrieved 18 February 2019.
  88. ↑ "Historic Fellows". AAAS. Retrieved 18 February 2019.
  89. ↑ "Golden Plate Awardees of the American Academy of Achievement". www.achievement.org. American Academy of Achievement.
  90. ↑ Oakes, Elizabeth H., ed. (2007). "Mary-Claire King". Encyclopedia of World Scientists. Detroit: Infobase Publishing. pp. 182–183. ISBN   9781438118826.
  91. ↑ "Williams College Celebrates 230th Commencement". Williams College. 2019. Retrieved 2 June 2019.
  92. ↑ "2018 Honorary Degree Recipients". University of British Columbia. 2018. Retrieved 12 February 2019.
  93. ↑ "195th Congregation (2016) Mary-Claire KING Doctor of Science honoris causa". The University of Hong Kong. Retrieved 12 February 2019.
  94. ↑ "Honorary Degrees". Tel Aviv University. Retrieved 18 February 2019.
  95. ↑ Dienst, Karin (June 3, 2008). "Princeton awards five honorary degrees". Princeton University News. Retrieved 18 February 2019.
  96. ↑ "Yale Confers 10 Honorary Doctorates at Commencement 2007 May 28, 2007". Yale University. May 28, 2007. Retrieved 12 February 2019.
  97. ↑ "Honorary Degrees". Brown University. Retrieved 18 February 2019.
  98. ↑ "Columbia Graduates 10,000 Students on May 21". Columbia News. May 21, 2003. Retrieved 18 February 2019.
  99. ↑ "11 awarded honorary degrees". Harvard Gazette. June 5, 2003. Retrieved 29 November 2016.
  100. ↑ "Bard College Catalogue". Bard College. Retrieved 18 February 2019.
  101. ↑ "Honorary Degrees". Smith College. Retrieved 18 February 2019.
  102. ↑ "Honorary Degree Recipients". Carleton College. Retrieved 12 February 2019.
  103. ↑ "Mary-Claire King, PhD". AACC. Retrieved 18 February 2019.
  104. ↑ Brysk, Alison (1990). The Political Impact of Argentina's Human Rights Movement: Social Movements, Transition and Democratization. Stanford, California: Stanford University.

Wikiquote-logo.svg Quotations related to Mary-Claire King at Wikiquote

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.